|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of TGF-β1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis.
|
23486519 |
2013 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
HS is able to antagonize, to some extent, tubular EMT and renal interstitial fibrosis caused by AA, which might be related to its inhibitory effects on the TGF-β1 and Snail expression.
|
26890569 |
2016 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The TGF-β1/SGK1 pathway is closely related to tubulointerstitial fibrosis in T2DM rats.
|
31841202 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
In this study, we investigated the role of the Sirt1 activator, SRT1720, in unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis and aimed to determine whether this role depends on the inhibition of oxidative stress and the TGF-β1/CTGF pathway.
|
28339034 |
2017 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Roscovitine attenuates renal interstitial fibrosis in diabetic mice through the TGF-β1/p38 MAPK pathway.
|
31029000 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
The effects of lefty1 were assessed by measuring the degree of tubulointerstitial fibrosis, tubular injury and atrophy, and also by monitoring the expression levels of α‑smooth muscle actin (α‑SMA), TGF‑β1, phosphorylated (p)‑Smad2/3, kidney injury molecular‑1 and endogenous lefty1.
|
26647776 |
2016 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
TGF-beta1 plays an important role in the pathogenesis of experimental and clinical glomerulosclerosis and tubulointerstitial fibrosis.
|
15942255 |
2005 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
RGD |
Expression of transforming growth factor-beta-inducible gene-h3 in normal and cyclosporine-treated rat kidney.
|
15007308 |
2004 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The mechanism underlying these effects may be related to inhibition of TGF-β1/Smad, and their downstream miR-21/PTEN signaling, leading to blocks of EMT process during RIF.
|
30304552 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Tranilast (N-[3,4-dimethoxycinnamoyl]anthranilic acid) is a synthetic compound that we have recently reported to inhibit transforming growth factor-beta1 (TGF-beta1)-induced tubulointerstitial fibrosis in the kidney.
|
16528248 |
2006 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
HMGB1, TGF-β1 and NF-κB may form a signaling pathway that leads to the occurrence of CAN, which induces renal interstitial fibrosis.
|
29285170 |
2017 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
RGD |
Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury.
|
23249995 |
2013 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
In the UUO model, administration of apelin significantly attenuated renal interstitial fibrosis, as evidenced by the maintenance of E-cadherin and laminin expression, and markedly suppressed expression of α-SMA, TGF-β1 and its type I receptor, as well as interstitial matrix components.
|
25164121 |
2014 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Central to the pathology of DN are cytokines and growth factors such as TGF-beta (transforming growth factor beta) superfamily members, including BMPs (bone morphogenetic protein) and TGF-beta1, which play key roles in fibrogenic responses of the kidney, including podocyte loss, mesangial cell hypertrophy, matrix accumulation and tubulointerstitial fibrosis.
|
18793165 |
2008 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
Transforming growth factor-{beta}1 induces Smad3-dependent {beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis.
|
20709799 |
2010 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
CL treatment improved TAC-induced renal dysfunction and decreased renal interstitial fibrosis (reduced expression of e-cadherin and TGFβ-1) and interstitial inflammation (decreased infiltration of ED-1-positive and osteopontin-positive cells).
|
31200653 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
Bradykinin induced similar changes in receptor levels and prevented transforming growth factor-beta(1)-induced tubulointerstitial fibrosis.
|
18402547 |
2008 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Therefore, over-expression of PHB suppresses renal interstitial fibroblasts proliferation and cell phenotypic change induced by TGF-beta1, which indicates PHB as a potential therapeutic target to halt the progression of TIF.
|
17043753 |
2007 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
In summary, IHG-1, which increases in diabetic nephropathy, may enhance the actions of TGF-beta1 and contribute to the development of tubulointerstitial fibrosis.
|
18508967 |
2008 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, in TGF-β1 stimulated HK-2 cells, AS-IV clearly inhibited the expression levels of α-SMA, vimentin, collagen I, and miR-192 in a dose-dependent fashion while increased the expression level of E-cadherin in the same manner, indicating that AS-IV functioned the inhibitory role in renal tubulointerstitial fibrosis.
|
31497219 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Tubulointerstitial fibrosis that was indicated by the increases in collagen and transforming growth factor-β1 subsided by cilostazol.
|
28084586 |
2017 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Transforming growth factor β1 (TGF-β) promotes renal interstitial fibrosis in vivo and the expression of mesenchymal genes in vitro; however, most of its direct targets in epithelial cells are still elusive.
|
22556418 |
2012 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The results we obtained demonstrate that Nrf2 signaling pathway may perhaps offset the development of EMT, prompted by TGF-β1 and renal interstitial fibrosis.
|
31449784 |
2019 |
|
Tubulointerstitial fibrosis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
As one mechanism for the protection against diabetes-induced TIF and EMT, decreased Smad3 protein levels and, as a possible consequence, reduced TGF-β1 levels were observed in diabetic SMAD2 knockout mice.
|
29209813 |
2018 |
|
Tubulointerstitial fibrosis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The cells were also more prone (versus control) to TGFβ-1 induced epithelial-mesenchymal transition (EMT), a hallmark feature of the development of renal interstitial fibrosis, and characterized by development of spindle shape morphology, gene expression changes in EMT markers (Col1a3, Mmp9, Bmp7, and Ocln) and increased expression of N-Cadherin and Vimentin.
|
26172442 |
2015 |